Tesamorelin
A stabilized 44-amino-acid GHRH analog, notable as the only GHRH-class peptide with current FDA approval, specifically for reducing visceral fat in a defined patient population.
Research status: Strong clinical trial base; the reference point for GHRH efficacy data.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Selected references
- Journal of Clinical Endocrinology & Metabolism · 2010 Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials
- Lancet HIV · 2019 Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
- Journal of Clinical Endocrinology & Metabolism · 2019 The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
- U.S. FDA · 2025 EGRIFTA (tesamorelin) Prescribing Information
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.
Related in Growth Hormone (GHRH)